Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer

In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we evaluated the efficacy and safety and determined the effects of dose modifications on adverse events (AE) and therapy management of first‐line oral dacomitinib 45 mg compared with oral gefitinib 250 mg, each once dail...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Makoto, Kato, Terufumi, Niho, Seiji, Yamamoto, Noboru, Takahashi, Toshiaki, Nogami, Naoyuki, Kaneda, Hiroyasu, Fujita, Yuka, Wilner, Keith, Yoshida, Mizuki, Isozaki, Mitsuhiro, Wada, Shinsuke, Tsuji, Fumito, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226281/
https://www.ncbi.nlm.nih.gov/pubmed/32159882
http://dx.doi.org/10.1111/cas.14384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226281/
https://www.ncbi.nlm.nih.gov/pubmed/32159882
http://dx.doi.org/10.1111/cas.14384

Ejemplares similares